263 related articles for article (PubMed ID: 7614473)
1. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
2. Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system.
Evans R; Duffy TM; Kamdar SJ
Eur J Immunol; 1991 Aug; 21(8):1815-9. PubMed ID: 1907916
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
4. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
[TBL] [Abstract][Full Text] [Related]
5. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA
J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
[TBL] [Abstract][Full Text] [Related]
7. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
Reid I; Lundy J; Donohue JH
J Immunol; 1992 Apr; 148(8):2630-5. PubMed ID: 1532818
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer.
Shiohara T; Moellmann G; Jacobson K; Kuklinska E; Ruddle NH; Lerner AB
J Immunol; 1987 Mar; 138(6):1979-86. PubMed ID: 3493292
[TBL] [Abstract][Full Text] [Related]
10. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
Mezzanzanica D; Garrido MA; Neblock DS; Daddona PE; Andrew SM; Zurawski VR; Segal DM; Wunderlich JR
Cancer Res; 1991 Oct; 51(20):5716-21. PubMed ID: 1833054
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
Gallinger S; Hoskin DW; Mullen JB; Wong AH; Roder JC
Cancer Res; 1990 Apr; 50(8):2476-80. PubMed ID: 2138507
[TBL] [Abstract][Full Text] [Related]
12. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
[TBL] [Abstract][Full Text] [Related]
13. Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice.
Bock SN; Cameron RB; Kragel P; Mulé JJ; Rosenberg SA
Cancer Res; 1991 May; 51(10):2649-54. PubMed ID: 2021943
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
[TBL] [Abstract][Full Text] [Related]
15. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated redirected cytolysis against murine melanoma cells in vivo.
Usuba O; Ito M; Bona CA; Moran TM
Cancer Res; 1990 Sep; 50(18):6034-8. PubMed ID: 2144210
[TBL] [Abstract][Full Text] [Related]
17. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.
Yang JC; Perry-Lalley D; Rosenberg SA
J Biol Response Mod; 1990 Apr; 9(2):149-59. PubMed ID: 1971302
[TBL] [Abstract][Full Text] [Related]
18. Targeted cellular immunotherapy with bifunctional antibodies.
Nelson H
Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553
[TBL] [Abstract][Full Text] [Related]
19. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.
Restifo NP; Spiess PJ; Karp SE; Mulé JJ; Rosenberg SA
J Exp Med; 1992 Jun; 175(6):1423-31. PubMed ID: 1588273
[TBL] [Abstract][Full Text] [Related]
20. The in vivo depletion of V beta 17a+ T cells results in the inhibition of reticulum cell sarcoma growth in SJL/J mice. Evidence for the use of anticlonotypic antibody therapy in the control of malignancy.
Katz JD; Lebow LT; Bonavida B
J Immunol; 1989 Aug; 143(4):1387-95. PubMed ID: 2663994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
